Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLN-617 Alone and With Pembrolizumab in Advanced Solid Tumors
NCT06035744Phase 1Terminated
- Sponsor
- Cullinan Therapeutics
- Start
- Dec 2023
- Primary completion
- Jun 2026
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of CLN-617 in solid tumor, melanoma and head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by Cullinan Therapeutics. Primary endpoints: Dose Escalation at 24 Months, Dose Optimization at 24 Months and 1 more. Started Dec 2023; status: terminated.
02
Drugs
CLN-617
03
Conditions
solid tumormelanomahead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06035744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06035744.